Oxidation of HMG-CoA reductase inhibitors by tert-butoxyl and 1,1-diphenyl-2-picrylhydrazyl radicals: Model reactions for predicting oxidatively sensitive compounds during preformulation
Sb. Karki et al., Oxidation of HMG-CoA reductase inhibitors by tert-butoxyl and 1,1-diphenyl-2-picrylhydrazyl radicals: Model reactions for predicting oxidatively sensitive compounds during preformulation, J PHARM SCI, 89(12), 2000, pp. 1518-1524
Hydrogen atom abstraction rate constants for the reaction of tert-butoxyl a
nd 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical with the HMG-CoA reductase
inhibitors lovastatin, simvastatin, and statins I-IV were measured. This se
ries of diene-containing drugs is known to be prone to oxidation. The tert-
butoxyl radical was generated by the thermolysis of di-tert-butylperoxyoxal
ate at 40 degreesC. A competitive kinetic method was used to determine the
relative rate of hydrogen atom abstraction by tert-butoxyl radical to beta
-scission. The absolute rate constants were calculated using the experiment
ally determined product ratios of t-butanol to acetone and the known rate o
f beta -scission of tert-butoxyl radical. The rate constants for the reacti
on with DPPN: radical were measured spectrophotometrically by monitoring th
e loss of DPPH radical as a function of substrate concentration. The rate c
onstants correlate well with the structure of the molecules studied. These
kinetic techniques allow for oxidatively sensitive compounds to be identifi
ed early in the drug development cycle. The tert-butoxyl radical, a strong
hydrogen atom abstractor, is representative of the hydroxyl ( . OH) and alk
oxyl ( . OR) radicals; in contrast the DPPH radical, a much weaker radical,
is a good kinetic model for hydroperoxyl ( . OOH) and peroxyl ( . OOR) rad
icals. These kinetic methods can be used to quantitatively assess the labil
ity of drug candidates towards reaction with oxygen-centered radicals at an
early stage of development and facilitate the design of inhibiting strateg
ies. (C) 2000 Wiley-Liss, Inc. and the American Pharmaceutical Association
J Pharm Sci 89:1518-1524, 2000.